Haoyan(Michael) received his Bachelor’s degree from the Biomedical Engineering Department at Southeast University in China. He came to the USA for his MS degree at the University of Florida and Cornell University. He then obtained his Ph.D. degree focused on targeted drug delivery at Case Western Reserve University. He spent nearly five years at GlaxoSmithKlein in parenteral formulation and drug product development supporting varieties of modalities including small molecules, oligonucleotides and monoclonal antibodies. Currently, he leads the formulation team within discovery research at Spark Therapeutics to advance new therapeutic modalities for gene transfer. Haoyan has published 22 peer-review papers and two patents.
